keyword
MENU ▼
Read by QxMD icon Read
search

conbercept

keyword
https://www.readbyqxmd.com/read/27922068/changes-in-retinal-nerve-fiber-layer-thickness-after-multiple-injections-of-novel-vegf-decoy-receptor-conbercept-for-various-retinal-diseases
#1
Zhihua Zhang, Xiaolu Yang, Huiyi Jin, Yuan Qu, Yuan Zhang, Kun Liu, Xun Xu
Conbercept is a recombinant fusion protein with high affinity for all vascular endothelial growth factor isoforms and placental growth factor. The repeated intravitreal injection of conbercept may cause intraocular pressure (IOP) fluctuations and long-term suppression of neurotrophic cytokines, which could lead to retinal nerve fiber layer (RNFL) damage. This retrospective fellow-eye controlled study included 98 eyes of 49 patients. The changes in IOP and RNFL thickness as well as the correlation between RNFL changes and associated factors were evaluated...
December 6, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27893623/efficacy-and-safety-of-intravitreal-conbercept-injections-in-macular-edema-secondary-to-retinal-vein-occlusion
#2
Zuhua Sun, Haiying Zhou, Bing Lin, Xuan Jiao, Yingdong Luo, Feng Zhang, Shanshan Tao, Quan Wu, Zunhong Ke, Xiaoling Liu
PURPOSE: To assess the efficacy and safety of intravitreal conbercept injections in patients with macular edema secondary to retinal vein occlusion (RVO). METHODS: A prospective, Phase II clinical trial was performed on 60 patients with macular edema secondary to RVO. Thirty patients had branch RVO (BRVO) and 30 had central RVO (CRVO). Each patient received intravitreal injections of conbercept monthly up to 3 months, followed by monthly evaluation and injection pro re nata to Month 9...
November 23, 2016: Retina
https://www.readbyqxmd.com/read/27877088/aloe-emodin-suppresses-hypoxia-induced-retinal-angiogenesis-via-inhibition-of-hif-1%C3%AE-vegf-pathway
#3
Jianming Wu, Xiao Ke, Wei Wang, Hongcheng Zhang, Na Ma, Wei Fu, Manxi Zhao, Xiaoping Gao, Xiaofeng Hao, Zhirong Zhang
Background: Aloe-emodin (AE) has been reported to possess the antiangiogenic effect on laser induced choroidal neovascularization. AE inhibits the vessel formation in the zebrafish embryos. However, it is still unclear whether AE can alleviate neovascularization. Here, we investigated the inhibitory effect of AE on the hypoxia-induced retinal neovascularization and the possible mechanisms. Methods: We established a vascular endothelial growth factor (VEGF) secretion model under chemical induced hypoxia by exposure of 150 µM CoCl2 to the ARPE-19 cells, then treated the cells with different concentrations of AE (0...
2016: International Journal of Biological Sciences
https://www.readbyqxmd.com/read/27847621/fusion-proteins-for-treatment-of-retinal-diseases-aflibercept-ziv-aflibercept-and-conbercept
#4
REVIEW
João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Eduardo Amorim Novais, Michel Eid Farah, Eduardo Büchele Rodrigues
In the last few years, monoclonal antibodies have revolutionized the treatment of retinal neovascular diseases. More recently, a different class of drugs, fusion proteins, has provided an alternative treatment strategy with pharmacological differences. In addition to commercially available aflibercept, two other drugs, ziv-aflibercept and conbercept, have been studied in antiangiogenic treatment of ocular diseases. In this scenario, a critical review of the currently available data regarding fusion proteins in ophthalmic diseases may be a timely and important contribution...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27779169/comparison-of-the-1-year-outcomes-of-conbercept-therapy-between-two-different-angiographic-subtypes-of-polypoidal-choroidal-vasculopathy
#5
Yong Cheng, Xuan Shi, Jin-Feng Qu, Ming-Wei Zhao, Xiao-Xin Li
BACKGROUND: Polypoidal choroidal vasculopathy (PCV) is characterized by the presence of polyps with or without a branching vascular network and more prevalent among Asians. The aim of this study was to compare the outcomes of conbercept therapy between two different angiographic subtypes of PCV. METHODS: Fifty-eight patients of PCV were classified into two phenotypes according to indocyanine green angiography (ICGA). In Type 1, both feeder and draining vessels are visible on ICGA and network vessels are numerous...
2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/27777791/intravitreal-conbercept-injection-with-and-without-grid-laser-photocoagulation-in-the-treatment-of-diffuse-diabetic-macular-edema-in-real-life-clinical-practice
#6
Yule Xu, Ao Rong, Yanlong Bi, Wei Xu
Purpose. To evaluate the efficacy of intravitreal conbercept (IVC) plus modified grid laser photocoagulation (MGP) versus IVC alone for treatment of diffuse diabetic macular edema (DDME). Methods. In this retrospective study, 51 DDME patients were treated with either IVC alone (IVC group) or IVC plus MGP (combined group) with 12 months of follow-up. The clinical records of those patients were reviewed. Results. 26 patients (31 eyes) received IVC alone and 25 patients (30 eyes) received combined therapy. At month 12, the mean best-corrected visual acuity (BCVA) letter score improvement was 9...
2016: Journal of Ophthalmology
https://www.readbyqxmd.com/read/27729769/formononetin-an-active-compound-of-astragalus-membranaceus-fisch-bunge-inhibits-hypoxia-induced-retinal-neovascularization-via-the-hif-1%C3%AE-vegf-signaling-pathway
#7
Jianming Wu, Xiao Ke, Na Ma, Wei Wang, Wei Fu, Hongcheng Zhang, Manxi Zhao, Xiaoping Gao, Xiaofeng Hao, Zhirong Zhang
BACKGROUND: It has been reported that formononetin (FMN), one of the main ingredients from famous traditional Chinese medicine "Huang-qi" (Astragalus membranaceus [Fisch] Bunge) for Qi-tonifying, exhibits the effects of immunomodulation and tumor growth inhibition via antiangiogenesis. Furthermore, A. membranaceus may alleviate the retinal neovascularization (NV) of diabetic retinopathy. However, the information of FMN on retinal NV is limited so far. In the present study, we investigated the effects of FMN on the hypoxia-induced retinal NV and the possible related mechanisms...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27617537/serum-levels-of-vascular-endothelial-growth-factor-before-and-after-intravitreal-injection-of-ranibizumab-or-conbercept-for-neovascular-age-related-macular-degeneration
#8
Enzhong Jin, Yujing Bai, Ling Luo, Lvzhen Huang, Xuemei Zhu, Xue Ding, Huijun Qi, Mingwei Zhao
OBJECTIVE: To investigate the serum levels of vascular endothelial growth factor (VEGF) before and after intravitreal injection of conbercept or ranibizumab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy patients. METHODS: This study is a prospective, interventional case series and involved 28 patients, 18 treated with 0.5 mg of conbercept and 10 treated with 0.5 mg of ranibizumab. Serum concentrations of VEGF were determined by enzyme-linked immunosorbent assay before the injection and at 1 day, 1 week, and 1 month after anti-VEGF treatments...
September 8, 2016: Retina
https://www.readbyqxmd.com/read/27514451/analysis-and-quality-control-of-carbohydrates-in-therapeutic-proteins-with-fluorescence-hplc
#9
Kun Liu, Jian Huang, Delun Luo, Kai Xu, Zhigang Wu, Xun Xu
Conbercept is an Fc fusion protein with very complicated carbohydrate profiles which must be carefully monitored through manufacturing process. Here, we introduce an optimized fluorescence derivatization high-performance liquid chromatographic method for glycan mapping in conbercept. Compared with conventional glycan analysis method, this method has much better resolution and higher reproducibility making it excellent for product quality control.
September 16, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/27034822/a-randomized-controlled-trial-of-conbercept-pretreatment-before-vitrectomy-in-proliferative-diabetic-retinopathy
#10
Xiaochun Yang, Jianbiao Xu, Ruili Wang, Yan Mei, Huo Lei, Jun Liu, Ting Zhang, Haiyan Zhao
Purpose. To determine the efficacy and safety of preoperative intravitreal conbercept (IVC) injection before vitrectomy for proliferative diabetic retinopathy (PDR). Methods. 107 eyes of 88 patients that underwent pars plana vitrectomy (PPV) for active PDR were enrolled. All patients were assigned randomly to either preoperative IVC group or control group. Follow-up examinations were performed for three months after surgery. The primary bioactivity measures were severity of intraoperative bleeding, incidence of early and late recurrent VH, vitreous clear-up time, and best-corrected visual acuity (BCVA) levels...
2016: Journal of Ophthalmology
https://www.readbyqxmd.com/read/26850582/-clinical-observation-of-a-new-anti-vegf-drugs-conbercept-for-wet-age-related-macular-degeneration
#11
Hang Lu, Jinglin Cui, Hui Dong, Binjiang Luo, Weiwei Xiu, Huimei Li
OBJECTIVE: To observe the efficacy and safety of intravitreal injection of conbercept, a new drugs of VEGFR fusion proteins, on wet age-related macular degeneration (wAMD). METHODS: To analyze retrospectively the clinical data of 58 patients with wet wAMD, which was diagnosed by examination of ETDRS charts, color fundus photograph, fluorescein angiography (FFA) and optical coherence tomography (OCT), were underwent intravitreal injection conbercept 0.5 mg (0.05 ml of 10 g/L)...
November 2015: [Zhonghua Yan Ke za Zhi] Chinese Journal of Ophthalmology
https://www.readbyqxmd.com/read/26630313/intravitreal-conbercept-kh902-for-surgical-treatment-of-severe-proliferative-diabetic-retinopathy
#12
Long Su, Xinjun Ren, Huiyu Wei, Li Zhao, Xiaomin Zhang, Juping Liu, Chang Su, Liangzhang Tan, Xiaorong Li
PURPOSE: To evaluate the role, safety, and effectiveness of intravitreal conbercept (KH902) injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy. METHODS: A randomized controlled trial was performed on 36 eyes of 36 patients affected by vitreous hemorrhage and tractional retinal detachment, which occurred as a consequence of active proliferative diabetic retinopathy. The patients were randomly assigned to two groups...
May 2016: Retina
https://www.readbyqxmd.com/read/26595362/efficacy-of-intravitreal-injection-of-conbercept-in-polypoidal-choroidal-vasculopathy-subgroup-analysis-of-the-aurora-study
#13
Jinfeng Qu, Yong Cheng, Xiaoxin Li, Liyun Yu, Xiao Ke
PURPOSE: To evaluate the efficacy of different doses of conbercept in patients with polypoidal choroidal vasculopathy in the AURORA study. METHODS: Retrospective subgroup analyses of 12-month data from the AURORA study. Fifty-three patients (32 in 0.5-mg group and 21 in 2.0-mg group) diagnosed with polypoidal choroidal vasculopathy in AURORA study were retrospectively evaluated. Efficacy outcomes were compared between the two dosage groups. RESULTS: At Month 12, mean changes in best-corrected visual acuity from baseline were 14...
May 2016: Retina
https://www.readbyqxmd.com/read/26532374/cost-effectiveness-analysis-of-conbercept-versus-ranibizumab-for-the-treatment-of-age-related-macular-degeneration-in-china
#14
M Zhao, W Feng, L Zhang, X Ke, W Zhang, J Xuan
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/26289225/conbercept-kh-902-for-the-treatment-of-neovascular-age-related-macular-degeneration
#15
Thanh T Nguyen, Robyn Guymer
Age-related macular degeneration (AMD) is a progressive, degenerative disease of the retina that occurs with increasing incidence with age and ranks third among the global causes of visual impairment. VEGF has been implicated in the development and progression of neovascular AMD. Drugs that block VEGF, leading to regression of the abnormal blood vessels, are the mainstay of treatment of neovascular AMD, particularly for subfoveal neovascular lesions. Anti-VEGF agents currently in use in neovascular AMD are pegaptanib (Macugen(®)), ranibizumab (Lucentis(®)), bevacizumab (Avastin(®)) and a soluble VEGF receptor decoy aflibercept (Eylea(®))...
2015: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/26250840/conbercept-kh-902-for-the-treatment-of-neovascular-age-related-macular-degeneration
#16
Thanh T Nguyen, Robyn Guymer
Age-related macular degeneration (AMD) is a progressive, degenerative disease of the retina that occurs with increasing incidence with age and ranks third among the global causes of visual impairment. VEGF has been implicated in the development and progression of neovascular AMD. Drugs that block VEGF, leading to regression of the abnormal blood vessels, are the mainstay of treatment of neovascular AMD, particularly for subfoveal neovascular lesions. Anti-VEGF agents currently in use in neovascular AMD are pegaptanib (Macugen(®)), ranibizumab (Lucentis(®)), bevacizumab (Avastin(®)) and a soluble VEGF receptor decoy aflibercept (Eylea(®))...
August 7, 2015: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/26170626/anti-vegf-treatment-for-myopic-choroid-neovascularization-from-molecular-characterization-to-update-on-clinical-application
#17
REVIEW
Yan Zhang, Qian Han, Yusha Ru, Qiyu Bo, Rui Hua Wei
Choroidal neovascularization (CNV) secondary to pathologic myopia has a very high incidence in global, especially in Asian, populations. It is a common cause of irreversible central vision loss, and severely affects the quality of life in the patients with pathologic myopia. The traditional therapeutic modalities for CNV secondary to pathologic myopia include thermal laser photocoagulation, surgical management, transpupillary thermotherapy, and photodynamic therapy with verteporfin. However, the long-term outcomes of these modalities are disappointing...
2015: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/25960634/profile-of-conbercept-in-the-treatment-of-neovascular-age-related-macular-degeneration
#18
REVIEW
Xinmin Lu, Xiaodong Sun
In developed countries, age-related macular degeneration (AMD) is the leading cause of irreversible blindness in individuals over the age of 65 years. Vascular endothelial growth factor (VEGF) plays a vital role in the formation of neovascular AMD. VEGF regulates angiogenesis, enhances vascular permeability, and drives the formation of choroidal neovascularization. As a result of the introduction of anti-VEGF drugs, the incidence of blindness from neovascular AMD has greatly reduced. Anti-VEGF drugs are used as a first-line treatment for neovascular AMD...
2015: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/25737631/observation-of-total-vegf-level-in-hyperglycemic-mouse-eyes-after-intravitreal-injection-of-the-novel-anti-vegf-drug-conbercept
#19
Liping Du, Hui Peng, Quan Wu, Meidong Zhu, Delun Luo, Xiao Ke, Peizeng Yang, Bo Lei
PURPOSE: Conbercept (KH902), a novel recombinant, soluble vascular endothelial growth factor (VEGF) receptor-IgG fusion protein, has been developed as a new drug for ocular neovascularization and macular edema. The present study aims to clarify the changes in conbercept levels, VEGF, and intraocular pressure (IOP) after the intravitreal injection of conbercept into diabetic mouse eyes. METHODS: Five-week-old C57BL/6 mice were injected with streptozotocin to induce diabetes...
2015: Molecular Vision
https://www.readbyqxmd.com/read/24793528/safety-and-efficacy-of-conbercept-in-neovascular-age-related-macular-degeneration-results-from-a-12-month-randomized-phase-2-study-aurora-study
#20
RANDOMIZED CONTROLLED TRIAL
Xiaoxin Li, Gezhi Xu, Yusheng Wang, Xun Xu, Xiaoling Liu, Shibo Tang, Feng Zhang, Junjun Zhang, Luosheng Tang, Quan Wu, Delun Luo, Xiao Ke
PURPOSE: To assess the safety and efficacy of multiple injections of 0.5 and 2.0 mg conbercept using variable dosing regimens in patients with neovascular age-related macular degeneration (AMD). DESIGN: Randomized, double-masked, multicenter, controlled-dose, and interval-ranging phase 2 clinical trial divided into a 3-month loading phase followed by a maintenance phase. PARTICIPANTS: Patients with choroidal neovascularization secondary to AMD with lesion sizes of 12 disc areas or less and a best-corrected visual acuity (BCVA) letter score of between 73 and 24 were enrolled...
September 2014: Ophthalmology
keyword
keyword
81384
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"